"Take without regard to meals."@en . . "5 weeks"@en . . . . "(5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide"@en . . . . . . . . . . . . . . "164656-23-9"@en . "Dutasteride inhibits the conversion of testosterone to 5 alpha-dihydrotestosterone (DHT), which is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. Testosterone is converted to DHT by the enzyme 5 alpha-reductase, which exists as 2 isoforms, type 1 and type 2. Dutasteride is a competitive and specific inhibitor of both type 1 and type 2 5 alpha-reductase isoenzymes, with which it forms a stable enzyme complex. Dissociation from this complex has been evaluated under in vitro and in vivo conditions and is extremely slow. Dutasteride does not bind to the human androgen receptor."@en . . . "alpha,alpha,alpha,Alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide"@en . . . . . . . . . "Dutasteride"@en . "* 300 to 500 L"@en . "approved"@en . "Dutasteride is extensively metabolized in humans. Dutasteride and its metabolites were excreted mainly in feces."@en . "# Keam SJ, Scott LJ: Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68(4):463-85. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18318566 # Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL: Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol. 2009 Feb;181(2):621-6. Epub 2008 Dec 16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19091347"@en . "Dutasteride belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT). Finasteride also belongs to this group, but while dutasteride inhibits both isoforms of 5-alpha reductase, finasteride inhibits only one. Even so, a clinical study done by GlaxoSmithKline, the EPICS trial, did not find dutasteride to be more effective than finasteride in treating BPH. [Wikipedia]"@en . . . . "For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for surgery."@en . "60%"@en . . . . "Manne Reddy, \"Forms of dutasteride and methods for preparation thereof.\" U.S. Patent US20040077673, issued April 22, 2004."@en . "Highly bound to albumin (99%) and \u03B1-1 acid glycoprotein (96.6%). "@en . . "investigational"@en . . . . . . . . . "Humans and other mammals"@en . . . . . . . . . . . . . . . .